title: Novel Therapeutics for Pancreatic Adenocarcinoma.
abstract: The last decade has seen significant developments in the use of combination systemic therapy for advanced pancreatic ductal adenocarcinoma (PDAC), with median survival approaching 1 year for select patients treated with FOLFIRINOX in the metastatic setting. However, it is sobering that these developments have been achieved with the use of traditional cytotoxics rather than from successes in the more modern fields of molecularly targeted therapies or immunotherapy. This article highlights several promising therapeutic approaches to PDAC currently under clinical evaluation, including immune therapies, molecularly targeted therapies, strategies for stromal depletion, and targeted therapy for genetically selected patients.
authors.affiliation: Gastrointestinal Oncology Service, Department of Medicine, Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 300 East 66th Street, New York, NY 10065, USA.
authors.forename: Maeve A
authors.initials: MA
authors.lastname: Lowery
authors.affiliation: Gastrointestinal Oncology Service, Department of Medicine, Rubenstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, Weill Medical College of Cornell University, 300 East 66th Street, New York, NY 10065, USA. Electronic address: oreillye@mskcc.org.
authors.forename: Eileen M
authors.initials: EM
authors.lastname: O'Reilly
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000627:therapeutic use; D021441:Carcinoma, Pancreatic Ductal / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000401:mortality; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D058990:Molecular Targeted Therapy / Q000379:methods*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology / Q000401:mortality; D016032:Randomized Controlled Trials as Topic
chemical_list: D019496:Cancer Vaccines
keywords: BRCA; Immunotherapy; KRAS; Novel therapeutics; Pancreatic adenocarcinoma; Stromal targeting